ArticleCell death & disease2026
HOXA9 orchestrates EMT and metastasis in oral cancer via transcriptional activation of vimentin and β-catenin signaling.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Identifying biomarkers of epithelial‒mesenchymal transition (EMT) and metastasis play a decisive role in the prognosis and clinical management of Oral cancer (OC). Homeobox A9 (HOXA9), an imperative regulator of embryogenesis and endothelial cell proliferation, is aberrantly expressed in several malignancies, including OC. To date, HOXA9-mediated molecular mechanisms and their functional roles in EMT and OC metastasis remain poorly understood. In this study, we observed significant upregulation of HOXA9 in OC samples with lymph node-positive stage and higher histological grade. Notably, we demonstrated that retroviral-mediated knockdown of HOXA9 impairs proliferation, migration, and invasion while promoting apoptosis and cell cycle arrest. A substantial reduction in tumor volume and diminished lung metastasis was observed in nude mice receiving HOXA9-knockdown cells. Transcriptomic analysis of HOXA9-depleted cells revealed the downregulation of multiple pathways, with the most significant being "pathways in cancer". We further demonstrated that HOXA9 transcriptionally activates VIM to promote EMT and it also facilitates β-catenin nuclear translocation, which subsequently activates downstream target genes driving Wnt/β-catenin cascade. Our study also unveils HOXA9-driven molecular interplay in which HOXA9-dependent transcriptional activation of VIM triggers Wnt/β-catenin cascade in OC. Furthermore, we demonstrated that hypomethylated CpGs at HOXA9 promoter (spanning -4201bp to -3574bp upstream of TSS) in stage III/IV tumors showed a significant inverse correlation between hypomethylation and gene upregulation. Consistently, analysis of the same distal promoter region revealed the enrichment of activating histone modifications, further supporting its transcriptional permissive state. Collectively, our study uncovers a novel mechanism by which epigenetically altered HOXA9 serves as a potential inducer of EMT through regulation of VIM/Wnt-β-catenin/EMT signaling axis. These findings signify HOXA9 as a promising biomarker in OC and targeting HOXA9 could be an effective strategy to improve clinical outcome of patients diagnosed with advanced stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.